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542 The Journal of Thoracic and CardioObjective: For children in whom graft failure develops after cardiac transplantation,
retransplantation is often considered. Although some centers have reported equiv-
alent results for retransplantation as for primary transplantation, this strategy re-
mains controversial. We sought to examine outcomes after retransplantation in
children and to identify risk factors for mortality.
Methods: United Network for Organ Sharing records of heart transplantation for
subjects younger than 18 years from 1987 to 2004 were reviewed. Indications for
retransplantation and patient characteristics were evaluated. Analysis was per-
formed with proportional hazards regression, controlling for other potential risk
factors.
Results: Among the 4227 pediatric heart transplants, there were 219 retransplants.
The most common indication for retransplantation was coronary allograft vascu-
lopathy (51%). The mean interval from initial heart transplant to retransplantation
was 4.7 3.8 years. Forty-two retransplants (19%) were performed within 180 days
of primary transplantation. Survivals at 1, 5, and 10 years after retransplantation
were 79%, 53%, and 44%, respectively. In multivariate analysis, retransplantation
was associated with significantly higher mortality than primary transplantation
(odds ratio 1.67, 95% confidence interval 1.32-2.12, P  .001). Patients who
underwent retransplantation within 180 days of primary transplantation had a
significantly lower 1-year survival than did other retransplant recipients (53% vs
86%, respectively, P  .02). Subjects who required mechanical ventilation before
retransplantation also had poorer survival (P  .03).
Conclusion: Survival after cardiac retransplantation in children is inferior to that
after primary transplantation. Although results are acceptable, the impact of
retransplantation on the availability of donor hearts requires further consider-
ation.
Heart transplantation plays an important role in the management of childrenwith congenital heart disease and cardiomyopathies. The outcome afterpediatric heart transplantation has improved dramatically during the past 20
years, and survival is superior to that reported for adult transplantation.1-2 None-
theless, graft failure occurs in a significant number of children, and the survival
half-life in children after heart transplantation is just greater than 12 years.1 Many
centers routinely undertake retransplantation for those children with graft failure.
Some single-center reports have suggested that survival after retransplantation is
equivalent to that after primary transplantation.3-5 Data from adults, however,
suggest that retransplantation is associated with significantly poorer outcome than
primary transplantation, with fewer than 40% of subjects surviving to 5 years.6-7 In
this study we examined the data from the United Network for Organ Sharing
(UNOS) to analyze the outcome and risk factors for children who undergo retrans-
plantation.
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This study was approved by the institutional review board of
Children’s Healthcare of Atlanta. Data for this analysis were
supplied by UNOS. The data set consisted of the Transplant
Candidate Registration form, the Transplant Recipient Registra-
tion form, and the Transplant Recipient follow-up form. The
follow-up form was administered at repeated intervals. The pur-
pose of the study was to assess the impact of retransplantation on
patient survival and to examine recipient and donor-related factors
(Table 1) that might influence outcome.
Study Population
This study included all patients younger than 18 years who under-
went cardiac transplantation between May 1987 and December
2004. A total of 4227 heart transplants were performed; of these,
219 were retransplants. Subjects undergoing combined heart and
lung transplantation were not included in this analysis.
Statistical Analysis
Data are expressed as mean  SD or median and range as appro-
priate. Statistical analysis was performed by Fisher exact test, 2
test, Wilcoxon rank sum test, and Student t test. Kaplan-Meier
survival curve estimates, log-rank tests to compare survival curves,
and Cox proportional hazards model were performed to assess
multivariate associations between risk factors and freedom from
death. Analysis was performed with STATA version 6.0 (Stata
Corporation, College Station, Tex). All P values are 2-sided, and
confidence intervals are 95%.
Results
Cardiac retransplantation was performed at a median age of
9.0 years. The mean interval from initial transplantation to
retransplantation was 4.7  3.8 years. The ethnic compo-
sition of those undergoing retransplantation was as follows:
white (n 132), African American (n 50), Hispanic (n
22), Asian (n  6), mixed (n  5), American Indian (n 
TABLE 1. Variables analyzed for association with survival
Donor Recipient Procedure
Sex Sex Year of transplant
Age Age Ischemic time
Ethnicity Ethnicity
Mechanism
of death
Diagnosis
Blood type Retransplantation
Clinical ECMO*
infection Mechanical ventilation*
Inotropic medication*
Elevated creatinine*
PRA
Blood type
Clinical infection*
ECMO, Extracorporeal membrane oxygenation; PRA, panel-reactive
antibody. *At time of transplantation.2), and other (n  2). The indications for retransplantation
The Journal of Thoraciare shown in Table 2. The most common indication for
retransplantation was coronary allograft vasculopathy
(CAV), accounting for just more than half of the subjects. A
significant number of children were also described as hav-
ing nonspecific graft failure (16%), which in some cases
may also have represented CAV. There were 42 subjects
(19%) who underwent retransplantation for early primary
graft failure (retransplantation within 180 days of primary
transplantation). Reported causes of early primary graft
failure were primary failure (n  10), hyperacute rejection
(n  7), nonspecific graft failure (n  7), acute rejection
(n  7), CAV (n  2), and other (n  9).
Patients undergoing retransplantation were more likely
to be African American, older, female, allosensitized, and
with elevated serum creatinine relative to primary transplant
recipients (Table 3). Retransplant recipients had longer
waiting times than primary transplant recipients. The me-
dian waiting time for retransplant recipients was 37 days.
Retransplantation was associated with poorer overall sur-
vival than primary transplantation. The 1-, 5-, and 10-year
survivals after retransplantation were 79%, 53%, and 44%,
respectively. The 1-, 5-, and 10-year survivals after primary
transplantation were 83%, 70%, and 58%, respectively (Fig-
ure 1). The survival half-life after retransplantation was 5.6
years, compared with 13.2 years after primary transplanta-
tion. When multivariate analysis was undertaken, retrans-
plantation was identified as a significant risk factor for
mortality (odds ratio 1.67, 95% confidence interval 1.32-
2.12, P .001). Other variables found to be associated with
lower survival were earlier year of transplantation, female
sex, African American ethnicity, mechanical ventilation at
time of transplantation, congenital heart disease, and older
donor age (Table 4). The causes of death after retransplan-
tation were as follows: acute rejection (14%), CAV (14%),
infections (13%), nonspecific graft failure (8%), pulmonary
disease (7%), primary graft failure (5%), chronic rejection
(5%), multiorgan failure (5%), cerebrovascular disease
(3%), and all other causes (26%).
We subsequently attempted to identify factors associated
with poorer outcome among those subjects who underwent
retransplantation. Year of transplantation, need for extracor-
TABLE 2. Indications for retransplantation (n  219)
No. %
Acute rejection 19 9
Hyperacute rejection 7 3
Coronary allograft vasculopathy 111 51
Chronic rejection 16 7
Nonspecific graft failure 34 16
Primary failure 10 5
Other 22 10poreal membrane oxygenation, recipient ethnicity, recipient
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retransplantation. Rather, the need for mechanical ventila-
tion at time of retransplantation and early primary graft
failure (retransplantation within 180 days of initial trans-
plant) were identified as risk factors for mortality (P  .03
and P  .02, respectively). The 1-year survival for those
with early primary graft failure was only 53%, compared
with 86% for those who had late primary graft failure
(Figure 2). After exclusion of those with early primary graft
failure, the 1-year survival for retransplantation did not
differ from that of primary transplantation (86% vs. 83%,
respectively). However, by 5 years the survival was signif-
icantly worse for the retransplant recipients with late pri-
mary graft failure compared than for primary transplant
recipients (55% vs 70%, P.001).
Discussion
To date, more than 4000 children have undergone heart
transplantation in the United States.1 Intermediate-term sur-
vival has improved considerably, although the survival half-
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Figure 1. Kaplan-Meier survival plot after transplantation strati-
fied by primary transplantation (n  4008) versus retransplanta-
TABLE 3. Patient characteristics
Retra
(n
Median age at transplantation (y) 9
Female recipient (No.) 113
African American recipient (No.) 50
Inotropic medication (No.)* 84
UNOS status 2 (No.)* 62
Elevated serum creatinine (No.)†* 16
Mechanical ventilation (No.)* 53
Extracorporeal membrane oxygenation (No.)* 14
PRA 20% (No.) 45
Time on waiting list (d) 37
UNOS, United Network for Organ Sharing; PRA, Panel-reactive antibody.tion (n  219).
544 The Journal of Thoracic and Cardiovascular Surgery ● Augulife in children is less than 13 years.1 Retransplantation is
considered a reasonable alternative for these children. This
study, however, suggests that survival after retransplanta-
tion in children is significantly worse than that after primary
cardiac transplantation.
A number of institutions have reported promising results
fttlor pediatric retransplantation. Dearani and colleagues4 r
ported that the 3-year survival for children undergoing
retransplantation was 82% and was not significantly differ-
ent from that of those undergoing primary retransplantation
(77%). From our own institution, we reported that 3-year
survivals were also similar between retransplantation and
primary transplantation (78% vs 73%, respectively).3
Equivalent survivals in the two groups were noted even
though the retransplant recipients were more likely to be
UNOS status 1 and to be cared for in the intensive care unit.
In an earlier study, Michler and colleagues5 reported a
3-year survival of 47% in a cohort of 17 children undergo-
ing retransplantation. In this series as well, the mean graft
survival for retransplantation was similar to that of primary
transplantation. Conversely, in a recent analysis of the In-
ternational Society for Heart and Lung Transplantation data
TABLE 4. Risk factors for death after transplantation (n 
4227)
Variable
Hazard
ratio
95% Confidence
interval
P
value
Retransplantation 1.67 1.32-2.12 .001
Female recipient 1.18 1.06-1.32 .003
Later year of transplant 0.96 0.95-0.98 .001
Extracorporeal membrane
oxygenation*
1.92 1.50-2.48 .001
Mechanical ventilation* 1.30 1.13-1.50 .001
African American recipient 1.65 1.44-1.89 .001
Congenital heart disease 1.32 1.18-1.50 .001
Older donor age (effect/year) 1.009 1.004-1.01 .001
ntation
19)
Primary transplantation
(n  4008) P value
) 3 (0-17) .001
%) 1713 (42.7%) .01
%) 667 (16.6%) .02
%) 1559 (38.9%) .86
%) 1111 (27.8%) .98
) 87 (3.3%) .001
%) 787 (19.6%) .10
) 181 (4.5%) .26
%) 228 (6.9%) .001
18) 29 (1-1842) .04
me of transplantation. †Serum creatinine 2 mg/dL.nspla
 2
(0-17
(51.5
(22.8
(38.3
(29.5
(8.5%
(24.2
(6.4%
(23.6
(1-12*At the time of transplantation.
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retransplantation was associated with lower 1-year survival
but was not identified as a risk factor for decreased 5-year
survival. In our study spanning more than 15 years of
UNOS data, we found retransplantation to be associated
with significantly lower survival. The 5-year survival for
retransplantation was just greater than 50%. The median
survival after retransplantation was only 5.6 years. The
relatively large patient population and longer follow-up
allowed us to identify differences in survival for the retrans-
plant recipients that had not been identified in smaller,
single-center series.
Shorter time from primary heart transplantation to graft
failure was associated with poorer outcome after retrans-
plantation. Just more than half of the subjects with early
primary graft failure who underwent retransplantation were
alive at 1 year, compared with 86% for those undergoing
retransplantation for late graft failure. A similar association
was noted in adults in an analyses of the Cardiac Transplant
Research Database and the International Society of Heart
Lung Transplantation.6,7 Radovancevic and colleagues6 re-
ported that 1-year survival was less than 50% when retrans-
plantation was performed within 6 months of primary trans-
plantation. The poorer outcome of children and adults who
undergo retransplantation within 6 months of previous
transplantation is probably related to significant pretrans-
plantation morbidity and may reflect the need to accept a
suboptimal donor organ. In light of the relatively poor
outcome of children undergoing retransplantation for early
primary graft failure, the appropriateness of relisting in this
setting needs to be questioned. Some institutions have
adopted of policy limiting retransplantation only to those
patients with late primary graft failure. John and colleagues8
have reported survival greater than 90% in adults undergo-
Figure 2. Kaplan-Meier survival plot for patients undergoing re-
transplantation (n  219) stratified by early (<180 days from
initial transplantation) or late (>180 days from initial transplan-
tation) primary graft failure.ing retransplantation for late graft failure. Radovancevic
The Journal of Thoraciand colleagues6 have suggested that retransplantation for
CAV may be a reasonable approach in adult patients, espe-
cially when one considers improvements in the management
of CAV in recent years.
Even after exclusion of children undergoing retransplan-
tation for early primary graft failure, the overall survival for
retransplantation was still significantly less than that for
primary transplantation. The 5-year survival of patients
undergoing retransplantation for late primary graft failure
with indications such as CAV or late nonspecific graft
failure was only 55%, significantly less than that of patients
undergoing primary transplantation during the same era
(70%). The reasons for poorer survival after retransplanta-
tion may be manifold. Children listed for retransplantation
are more likely to be allosensitized.3 More than 20% of
retransplant recipients in this series had pretransplantation
panel-reactive antibody (PRAttttl) level greater than 20%. 
though our analysis did not find high PRA to be associated
with mortality, a recent report from the Pediatric Heart
Transplant Study Group demonstrated that elevated pre-
transplantation PRA was associated with lower survival and
shorter time to first rejection.9 In addition, other poorly
defined immunologic factors that may have predisposed
toward initial graft loss could lead to the loss of the retrans-
planted graft. Finally, social and environmental factors,
such as medication noncompliance, might be more common
among patients who undergo retransplantation.10
An extensive number of recipient and donor factors that
affect survival after pediatric heart transplantation have
been identified. These risk factors include recipient congen-
ital heart disease, recipient elevated PRA, recipient African
American ethnicity, and donor factors such as older age.1,11
Because of the relatively small number of children who
underwent retransplantation, analysis of potential risk fac-
tors within this subgroup of retransplant recipients was
limited. We did find that pretransplantation mechanical ven-
tilation was associated with poorer survival. Unlike studies
of adults undergoing retransplantation, we did not find that
later year of retransplantation was associated with improved
survival.6 It remains to be seen whether improvements in
immunosuppression will result in improved retransplanta-
tion outcomes in coming years.
Given that graft survival after retransplantation is infe-
rior to that after primary transplantation, questions as to the
appropriateness of retransplantation arise.12 Although wait-
ing times for pediatric heart transplants are less than for
adults, donor organ availability remains a concern. The
competition for such organs may increase in coming years,
because the increased number of pediatric heart transplants
in the early 1990s is likely to result in an increased number
of children, adolescents, and young adults who would be
candidates for retransplantation. It is possible that listing for
retransplantation might be deferred in some cases, particu-
c and Cardiovascular Surgery ● Volume 130, Number 2 545
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outcome for children diagnosed with CAV was quite poor
and that retransplantation would offer the best chance for
survival.13 Recent reports, however, have suggested im-
proved outcomes once CAV is recognized in children.14 In
addition, agents such as sirolimus and the use of coronary
artery stenting may offer an option to halt or reverse the
progression of CAV.15-18 Given these findings and the
stated limitations of retransplantation, medical interventions
may offer an alternative to or a means of delaying the need
for retransplantation for subjects in whom CAV develops.
In summary, retransplantation results in reasonable sur-
vival for children, although outcomes are inferior to those of
primary transplantation. When retransplantation is per-
formed in the setting of early primary graft failure, the
results are quite poor, and the appropriateness of this strat-
egy is questionable in light of the limited donor supply.
Further data regarding the natural history of CAV and
nonspecific graft failure will help in understanding the risks
and benefits of retransplantation in children.
We thank Ms Cynthia S. Cors from the UNOS Research
Department for assisting in data preparation.
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